Henlius Wins HKEX Approval for Full Circulation of 182.6 Million H Shares
I'm PortAI, I can summarize articles.
Shanghai Henlius Biotech, Inc. has received approval from the Stock Exchange of Hong Kong for the listing and trading of 182,645,856 converted H shares, allowing full circulation of these previously unlisted shares. This conversion involves 17 shareholders and represents about 33.61% of the company's total issued share capital, expected to enhance liquidity and broaden the investor base. The current analyst rating for Henlius's stock (HK:2696) is a Hold with a price target of HK$74.00.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments